Authors' recommendations:
Current evidence could not establish the benefit, harm, or cost-effectiveness of intrathecal drug delivery systems compared with current standards of care for managing refractory cancer pain in adults. Publicly funding intrathecal drug delivery systems for cancer pain would result in a budget impact of several hundred thousand dollars per year.
医疗服务技术 ; Drug Delivery Systems ; Neoplasms ; Technology Assessment, Biomedical
混合人群
Not Available
